JOP20210186A1 - مستضدات البروستاتا المستحدثة واستخداماتها - Google Patents

مستضدات البروستاتا المستحدثة واستخداماتها

Info

Publication number
JOP20210186A1
JOP20210186A1 JOP/2021/0186A JOP20210186A JOP20210186A1 JO P20210186 A1 JOP20210186 A1 JO P20210186A1 JO P20210186 A JOP20210186 A JO P20210186A JO P20210186 A1 JOP20210186 A1 JO P20210186A1
Authority
JO
Jordan
Prior art keywords
neoantigens
prostate
prostate neoantigens
vaccines
vectors
Prior art date
Application number
JOP/2021/0186A
Other languages
English (en)
Inventor
Kurtis E Bachman
Vipul Bhargava
David Pocalyko
Marco Gottardis
Darryl L Davis
Manuel Sepulveda
Derick Siegel
Pegah Safabakhsh
Vinod Krishna
Guido Leoni
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of JOP20210186A1 publication Critical patent/JOP20210186A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الكشف بمستضدات البروستاتا المستحدثة وعديدات النوكليوتيد التي تشفرها والنواقل والخلايا العائلة وجسيمات الفيروسات المأشوبة واللقاحات التي تتألف من المستضدات المستحدثة والجزيئات البروتينية التي ترتبط بمستضدات البروستاتا المستحدثة وطرق تحضيرها واستخدامها.
JOP/2021/0186A 2019-01-10 2020-01-09 مستضدات البروستاتا المستحدثة واستخداماتها JOP20210186A1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962790673P 2019-01-10 2019-01-10
US201962851273P 2019-05-22 2019-05-22
US201962883786P 2019-08-07 2019-08-07
US201962913969P 2019-10-11 2019-10-11
PCT/IB2020/050145 WO2020144615A1 (en) 2019-01-10 2020-01-09 Prostate neoantigens and their uses

Publications (1)

Publication Number Publication Date
JOP20210186A1 true JOP20210186A1 (ar) 2023-01-30

Family

ID=69191089

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0186A JOP20210186A1 (ar) 2019-01-10 2020-01-09 مستضدات البروستاتا المستحدثة واستخداماتها

Country Status (21)

Country Link
US (2) US11793843B2 (ar)
EP (1) EP3908311A1 (ar)
JP (1) JP2022516770A (ar)
KR (1) KR20210113655A (ar)
CN (1) CN113573729A (ar)
AU (1) AU2020207641A1 (ar)
BR (1) BR112021013507A2 (ar)
CA (1) CA3126462A1 (ar)
CL (2) CL2021001835A1 (ar)
CO (1) CO2021010006A2 (ar)
CR (1) CR20210370A (ar)
EC (1) ECSP21056536A (ar)
IL (1) IL284561A (ar)
JO (1) JOP20210186A1 (ar)
MA (1) MA54693A (ar)
MX (1) MX2021008392A (ar)
PE (1) PE20211660A1 (ar)
SG (1) SG11202107274VA (ar)
TW (1) TW202043256A (ar)
UY (1) UY38542A (ar)
WO (2) WO2020144614A1 (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
WO2022009052A2 (en) * 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009051A1 (en) * 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
CN117377683A (zh) * 2021-02-25 2024-01-09 西湖生物医药科技(杭州)有限公司 新抗原肽及其在治疗braf基因突变相关疾病中的用途
US20230190903A1 (en) * 2021-12-16 2023-06-22 Janssen Biotech, Inc. Prostate cancer vaccines and uses thereof

Family Cites Families (320)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US563536A (en) 1896-07-07 Bracket for swinging stages
US914623A (en) 1908-08-19 1909-03-09 Henry H Williams Process in the manufacture of generating-plates for x-ray machines.
US1051266A (en) 1910-09-26 1913-01-21 George I Rockwood Apparatus for operating alarms or other devices.
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6011146A (en) 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US5734023A (en) 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
DE69533569T2 (de) 1994-03-07 2006-01-05 Dendritic Nanotechnologies, Inc., Mt. Pleasant Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material
FR2719316B1 (fr) 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5972707A (en) 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
WO1996000295A1 (en) 1994-06-27 1996-01-04 The Johns Hopkins University Targeted gene delivery system
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
EP0790837A1 (en) 1994-12-21 1997-08-27 Novartis AG Oligonucleotide-dendrimer conjugates
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
IL122290A0 (en) 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
WO1997035996A1 (en) 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
HU224558B1 (hu) 1996-07-01 2005-10-28 äÁ>ŮÁ%Ć?> Eljárás rekombináns adenovírusok tisztítására
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
EP0948601B1 (en) 1996-12-13 2007-02-14 Schering Corporation Methods for purifying viruses
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
WO1998056370A2 (en) 1997-06-13 1998-12-17 Johns Hopkins University School Of Medicine Therapeutic nanospheres
ATE423789T1 (de) 1997-09-16 2009-03-15 Univ Oregon Health & Science Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6440442B1 (en) 1998-06-29 2002-08-27 Hydromer, Inc. Hydrophilic polymer blends used for dry cow therapy
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
DE60045138D1 (de) 1999-05-17 2010-12-02 Crucell Holland Bv Rekombinantes Adenovirus des Ad26-Serotyps
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
DE60038971D1 (de) 1999-10-22 2008-07-03 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US20030198953A1 (en) 2000-03-30 2003-10-23 Spytek Kimberly A. Novel proteins and nucleic acids encoding same
US20020192763A1 (en) 2000-04-17 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1598425A1 (en) 2000-11-23 2005-11-23 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
ATE378403T1 (de) 2000-11-30 2007-11-15 Medarex Inc Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
US20150329617A1 (en) 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
PL208712B1 (pl) 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
AU2003242820A1 (en) 2002-03-14 2003-09-22 Exonhit Therapeutics S.A. Variants of human kallikrein-2 and kallikrein-3 and uses thereof
DE60314823T3 (de) 2002-04-19 2017-11-16 Bavarian Nordic A/S Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
BR0316158A (pt) 2002-11-12 2005-09-27 Albert B Deisseroth Vacina de vetor adenoviral
CA2515890C (en) 2003-02-20 2013-09-17 Therion Biologics Corporation Novel insertion sites in pox vectors
US7834163B2 (en) 2003-06-26 2010-11-16 Exonhit Therapeutics S.A. Prostate specific genes and the use thereof as targets for prostate cancer therapy
EP2783699A1 (en) 2003-09-05 2014-10-01 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
GB2408507B (en) 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
EP1687033A4 (en) 2003-11-12 2008-06-11 Us Navy STRENGTHENING IMMUNE RESPONSE INDUCED BY A VACCINE AND HETEROLOGOUS AMPLIFICATION PROTECTION WITH ALPHAVIRUS REPLICON VACCINES
EP1687334B1 (en) 2003-11-24 2014-01-08 MicroVAX, LLC Mucin antigen vaccine
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
CA2993042A1 (en) 2004-01-23 2005-08-04 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
AU2005308594A1 (en) 2004-11-24 2006-06-01 St George's Enterprises Limited Diagnosis of prostate cancer
EP1683808A1 (en) 2005-01-25 2006-07-26 Het Nederlands Kanker Instituut Means and methods for breaking noncovalent binding interactions between molecules
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
EP1878744A1 (en) 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
GB2442048B (en) 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
GB2440529B (en) 2006-08-03 2009-05-13 Proimmune Ltd MHC Oligomer, Components Therof, And Methods Of Making The Same
US7910565B2 (en) 2006-09-01 2011-03-22 Wisconsin Alumni Research Foundation Prostate cancer vaccine
PT2073837E (pt) 2006-10-06 2014-09-22 Bavarian Nordic Inc Vírus vaccinia ankara modificado recombinante que codifica um antigénio her-2 em associação com um taxano para utilização no tratamento de cancro
US8037010B2 (en) 2007-02-28 2011-10-11 Numenta, Inc. Spatio-temporal learning algorithms in hierarchical temporal networks
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
ES2608604T3 (es) 2007-10-18 2017-04-12 Bavarian Nordic A/S Uso de MVA para tratar el cáncer de próstata
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP5710261B2 (ja) 2007-11-19 2015-04-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． ポックスウイルス腫瘍細胞崩壊性ベクター
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
WO2009111738A2 (en) 2008-03-06 2009-09-11 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
ES2836128T3 (es) 2008-04-16 2021-06-24 Univ Johns Hopkins Método para determinar variantes del receptor de andrógenos en cáncer de próstata
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP2546365B1 (en) 2008-09-03 2016-11-09 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
US8133724B2 (en) 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
JP5809978B2 (ja) 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−４３、−４５、−４６、−４７、−４８、−４９および−５０ならびにそれらの用途
CA2741834C (en) 2008-10-31 2022-04-05 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
EP2382328A2 (en) 2009-01-09 2011-11-02 The Regents of the University of Michigan Recurrent gene fusions in cancer
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
AU2010213892B2 (en) 2009-02-12 2014-10-23 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
US20110244026A1 (en) 2009-12-01 2011-10-06 Braydon Charles Guild Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
AU2011232435B2 (en) 2010-03-23 2016-01-28 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
EA201201435A1 (ru) 2010-04-20 2013-04-30 Генмаб А/С ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP4005592B1 (en) 2010-07-06 2022-10-12 GlaxoSmithKline Biologicals S.A. Virion-like delivery particles for self-replicating rna molecules
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
DK2591114T3 (en) 2010-07-06 2016-08-29 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
HRP20230326T1 (hr) 2010-08-31 2023-06-09 Glaxosmithkline Biologicals Sa Mali liposomi za isporuku rna koja kodira imunogen
DK4066857T3 (da) 2010-08-31 2023-02-20 Glaxosmithkline Biologicals Sa Pegylerede liposomer til afgivelse af immunogen-kodende RNA
SG188653A1 (en) 2010-09-29 2013-04-30 Uti Limited Partnership Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
WO2012044999A2 (en) 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
EP2502934B1 (en) 2011-03-24 2018-01-17 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
WO2012149522A1 (en) 2011-04-28 2012-11-01 Baylor College Of Medicine Recurrent chimeric rnas enriched in human prostate cancer as biomarkers
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
AU2012273182A1 (en) 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
WO2013006842A2 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
TR201900264T4 (tr) 2011-08-31 2019-02-21 Glaxosmithkline Biologicals Sa İmmünojen şifreleyici rna'nın verilmesi için pegile edilmiş lipozomlar.
CA2851251C (en) 2011-10-05 2023-09-12 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
JP6305925B2 (ja) 2011-10-11 2018-04-18 ノバルティス アーゲー 組換え自己複製ポリシストロニックｒｎａ分子
LT2771364T (lt) 2011-10-27 2019-09-10 Genmab A/S Heterodimerinių baltymų gamyba
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
SI2794905T1 (sl) 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
BR112014019049A2 (pt) 2012-02-02 2017-07-04 Univ Texas adenovirus imunogênico
US20160078168A1 (en) 2012-02-13 2016-03-17 Splicingcodes.Com Fusion transcript detection methods and fusion transcripts identified thereby
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
KR102171431B1 (ko) 2012-04-20 2020-10-30 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
NZ728024A (en) * 2012-05-25 2019-05-31 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
KR20170039774A (ko) 2012-07-30 2017-04-11 알렉스 와 힌 영 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
WO2014037124A1 (en) 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
CA2897858A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
WO2014206304A1 (zh) 2013-06-26 2014-12-31 广州市香雪制药股份有限公司 高稳定性的t细胞受体及其制法和应用
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
EP3412304A3 (en) 2013-10-23 2019-03-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
US20150202291A1 (en) 2013-11-05 2015-07-23 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
US20160271239A1 (en) 2013-11-05 2016-09-22 Bavarian Nordic A/S Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
CN105873902B (zh) 2013-11-18 2019-03-08 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
DK3071697T3 (da) 2013-11-22 2020-01-27 Dnatrix Inc Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er)
PT3074517T (pt) 2013-11-28 2021-11-03 Bavarian Nordic As Composições e métodos para indução de uma resposta imunitária intensificada usando vetores de poxvírus
US20170106065A1 (en) 2013-12-31 2017-04-20 Bavarian Nordic A/S Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
US9884075B2 (en) 2014-01-16 2018-02-06 California Institute Of Technology Domain-swap T cell receptors
ES2738582T3 (es) 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
EP3110953A1 (en) 2014-02-28 2017-01-04 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
WO2015143221A1 (en) 2014-03-19 2015-09-24 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
SG11201608798YA (en) 2014-04-23 2016-11-29 Modernatx Inc Nucleic acid vaccines
EP3142690B1 (en) 2014-05-13 2022-02-23 Bavarian Nordic A/S Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
CA2946606C (en) 2014-05-13 2023-06-06 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3
EP3760229A3 (en) 2014-05-15 2021-04-07 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20170106067A1 (en) 2014-06-12 2017-04-20 The Johns Hopkins University Combinatorial immunotherapy for pancreatic cancer treatment
EP3197490B1 (en) 2014-09-26 2023-06-21 Bavarian Nordic A/S Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
EP3256156A1 (en) 2015-02-13 2017-12-20 Transgene SA Immunotherapeutic vaccine and antibody combination therapy
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
JP6912384B2 (ja) 2015-04-22 2021-08-04 キュアバック アーゲー 癌疾患の処置のための、ｒｎａ含有組成物
WO2016172722A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
AU2016275312B2 (en) 2015-05-06 2021-12-23 Uti Limited Partnership Nanoparticle compositions for sustained therapy
EP3294326B1 (en) 2015-05-15 2021-04-21 CureVac AG Prime-boost regimens involving administration of at least one mrna construct
AU2016264623B2 (en) 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens
KR102489353B1 (ko) 2015-06-01 2023-01-17 캘리포니아 인스티튜트 오브 테크놀로지 특정 집단에 대한 항원으로 t 세포를 스크리닝하기 위한 조성물 및 방법
US10995140B2 (en) 2015-06-05 2021-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
US20180296663A1 (en) 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
CN107847544B (zh) 2015-07-20 2021-10-15 小利兰·斯坦福大学董事会 用多聚体结合试剂检测细胞表型和定量
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US20190008938A1 (en) * 2015-07-30 2019-01-10 Modernatx, Inc. Concatemeric peptide epitope rnas
SG10202001501QA (en) 2015-08-20 2020-04-29 Janssen Vaccines & Prevention Bv Therapeutic hpv18 vaccines
US20180318365A1 (en) 2015-10-19 2018-11-08 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
CN108430456B (zh) 2015-10-22 2022-01-18 摩登纳特斯有限公司 癌症疫苗
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
BR112018008783A8 (pt) 2015-10-30 2019-02-26 Aleta Biotherapeutics Inc terapia-alvo de câncer
EA201891093A1 (ru) 2015-11-03 2018-10-31 Янссен Байотек, Инк. Антитела, специфически связывающие pd-1, и их применение
AU2016363696B2 (en) 2015-12-02 2021-05-20 Innovative Targeting Solutions Inc. Single variable domain T-cell receptors
CA3015818A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Recombinant mva or mva.delta.e3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
BR112018016949A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center vírus vaccinia atenuado competente em relação à replicação como deleção de timidina quinase com ou sem a expressão de flt3l ou gm-csf humano para imunoterapia de câncer
EP3423473A4 (en) 2016-03-04 2019-10-30 New York University VIRUS VECTORS FOR EXPRESSING MULTIPLE EPITOPES OF TUMOR ASSOCIATED ANTIGENES TO INDUCT ANTITUMORIMMUNITY
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
EP3436048A4 (en) 2016-03-31 2019-11-27 Neon Therapeutics, Inc. NEOANTIGENES AND METHODS OF USE
WO2017177207A1 (en) 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
AU2017249424B2 (en) 2016-04-13 2023-08-24 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
RS63625B1 (sr) 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba
DK3458083T3 (da) 2016-05-18 2023-01-30 Modernatx Inc Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
CA3025648A1 (en) 2016-05-27 2017-11-30 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
CN109475613B (zh) 2016-06-14 2024-02-20 匹兹堡大学-属高等教育联邦体系 使癌细胞对胞毒免疫细胞攻击敏感的nkg2d活化配体蛋白表达
AU2017283118B2 (en) 2016-06-20 2019-02-07 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018033254A2 (en) 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
CN110494159A (zh) 2016-09-02 2019-11-22 扬森疫苗与预防公司 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
EP3293201B1 (en) 2016-09-12 2020-11-04 Targovax Oy Combining adenovirus and checkpoint inhibitors for treating cancer
CA3036799A1 (en) 2016-09-28 2018-04-05 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
ES2897217T3 (es) 2016-09-30 2022-02-28 Hoffmann La Roche Anticuerpos biespecíficos frente a p95HER2
WO2018075235A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
WO2018093907A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
JP2020500552A (ja) * 2016-11-23 2020-01-16 グリットストーン オンコロジー インコーポレイテッド 新生抗原のウイルスによる送達方法
WO2018102584A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
WO2018102585A1 (en) * 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
WO2018107011A1 (en) 2016-12-08 2018-06-14 City Of Hope P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof
US10459372B2 (en) 2017-01-31 2019-10-29 Hewlett-Packard Development Company, L.P. Binary ink developer (BID) assembly for liquid electrophotography (LEP) printing device
RU2022106357A (ru) 2017-02-01 2022-03-24 МОДЕРНАТиЭкс, ИНК. Противораковые рнк-вакцины
CA3052803A1 (en) 2017-02-07 2018-08-16 Nantcell, Inc. Maximizing t-cell memory and compositions and methods therefor
CA3053212C (en) 2017-02-09 2021-04-13 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
JP7229538B2 (ja) 2017-02-10 2023-03-01 ザ ロックフェラー ユニバーシティー 薬物標的を特定するための細胞型特異的プロファイリング方法
US20200377598A1 (en) 2017-03-03 2020-12-03 New York University Induction and Enhancement of Antitumor Immunity Involving Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens and Immune Checkpoint Inhibitors or Proteins
JP2020514370A (ja) 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
US20230241207A1 (en) 2017-04-03 2023-08-03 Neon Therapeutics, Inc. Protein antigens and uses thereof
US20200121774A1 (en) 2017-04-19 2020-04-23 University Of Iowa Research Foundation Cancer vaccines and methods of producing and using same
BR112019023477A2 (pt) 2017-05-08 2020-06-30 Gritstone Oncology, Inc. vetores de neoantígeno de alfavírus
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
WO2018223093A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University Universal cancer vaccines and methods of making and using same
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
SG11201913178WA (en) 2017-07-05 2020-01-30 Nouscom Ag Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
KR20200027499A (ko) 2017-07-12 2020-03-12 노우스콤 아게 암 치료용 신생항원 백신 조성물
WO2019012082A1 (en) 2017-07-12 2019-01-17 Nouscom Ag UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI)
KR20200037818A (ko) 2017-07-28 2020-04-09 얀센 백신스 앤드 프리벤션 비.브이. 이종성 repRNA 면역접종을 위한 방법 및 조성물
GB201713163D0 (en) * 2017-08-16 2017-09-27 Univ Oxford Innovation Ltd HPV vaccine
KR20200044000A (ko) 2017-08-24 2020-04-28 버베리안 노딕 에이/에스 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법
US11839655B2 (en) 2017-09-01 2023-12-12 Microvax, Llc Combination cancer therapy
AU2018333530B2 (en) 2017-09-13 2024-05-30 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
SG11202003799RA (en) 2017-11-03 2020-05-28 Nouscom Ag Vaccine t cell enhancer
US20210154277A1 (en) 2017-11-07 2021-05-27 Nektar Therapeutics Immunotherapeutic combination for treating cancer
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
BR112020013769A2 (pt) 2018-01-05 2020-12-01 Ottawa Hospital Research Institute vetores de ortopoxvírus modificados
US11690904B2 (en) 2018-01-06 2023-07-04 Emergex Vaccines Holding Limited MHC class I associated peptides for prevention and treatment of multiple flavi virus
BR112020013974A8 (pt) 2018-01-11 2022-10-18 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Ggmbh Formulação para administração de rna
MX2020007675A (es) 2018-01-19 2020-09-14 Janssen Pharmaceuticals Inc Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante.
WO2019147869A2 (en) 2018-01-24 2019-08-01 Virogin Biotech Canada Ltd Recombinant viral vaccines
CA3087044A1 (en) 2018-01-26 2019-08-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
US20190367568A1 (en) 2018-02-05 2019-12-05 Nantbio, Inc. Calreticulin and fusion proteins
US11376290B2 (en) 2018-03-14 2022-07-05 Wuhan Boweid Biotechnology Co., Ltd. Recombinant oncolytic virus, synthetic DNA sequence, and application thereof
WO2019191494A1 (en) 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
WO2019191780A1 (en) 2018-03-30 2019-10-03 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
TW202345890A (zh) 2018-04-23 2023-12-01 美商南特細胞公司 新抗原表位疫苗及免疫刺激組合物及方法
GB201807932D0 (en) 2018-05-16 2018-06-27 Redchenko Irina Compositions and methods for inducing an immune response
KR20210013589A (ko) 2018-05-23 2021-02-04 그릿스톤 온콜로지, 인코포레이티드 면역 체크포인트 억제제 공동-발현 벡터
WO2019226941A1 (en) 2018-05-23 2019-11-28 Gritstone Oncology, Inc. Shared antigens
JP2021525725A (ja) 2018-05-30 2021-09-27 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａワクチンおよびその使用
WO2019238023A1 (en) * 2018-06-11 2019-12-19 Chineo Medical Technology Co., Ltd. Neoantigen vaccines and uses thereof
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
WO2020014539A1 (en) 2018-07-11 2020-01-16 Epicentrx, Inc. Methods and compositions for targeting cancer cells for treatment
CA3106562A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
US20210393757A1 (en) 2018-10-01 2021-12-23 The Wistar Institute Melanoma Canine Vaccine Compositions and Methods of Use Thereof
WO2020073045A1 (en) 2018-10-05 2020-04-09 Nantcell, Inc. Cd40 and cd40l combo in an adenovirus vaccine vehicle
CA3113818A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
BR112021003499A2 (pt) 2018-10-19 2021-05-18 Nouscom Ag polipeptídeo, polinucleotídeo, vetor, coleção de dois ou mais vetores, composição farmacêutica e kit
AU2019374818A1 (en) 2018-11-07 2021-05-27 Modernatx, Inc. RNA cancer vaccines
WO2020097393A1 (en) 2018-11-07 2020-05-14 Gritstone Oncology, Inc. Alphavirus neoantigen vectors and interferon inhibitors
SG11202103243PA (en) 2018-11-15 2021-04-29 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine
MX2021005560A (es) 2018-11-20 2021-06-23 Bavarian Nordic As Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l).
EP3893925A4 (en) 2018-12-13 2023-01-18 Rhode Island Hospital INHIBITING THE GROWTH AND DEVELOPMENT OF ASPH-EXPRESSING TUMORS
CA3121430A1 (en) 2018-12-14 2020-06-18 Glaxosmithkline Biologicals Sa Heterologous prime boost vaccine compositions and methods
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CN109806390A (zh) 2019-01-07 2019-05-28 康希诺生物股份公司 一种SamRNA疫苗及其制备方法
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
EP3911678A1 (en) 2019-01-14 2021-11-24 Genentech, Inc. Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
EP3914355A1 (en) 2019-01-21 2021-12-01 Sanofi Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
EP3721899A1 (en) 2019-04-08 2020-10-14 China Medical University Combination therapies comprising dendritic cells-based vaccine and immune checkpoint inhibitor
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
WO2020247547A1 (en) 2019-06-03 2020-12-10 Geovax, Inc. Cancer vaccine compositions and methods for use thereof

Also Published As

Publication number Publication date
CN113573729A (zh) 2021-10-29
US11793843B2 (en) 2023-10-24
CL2022000373A1 (es) 2022-10-28
ECSP21056536A (es) 2023-02-28
IL284561A (en) 2021-08-31
WO2020144615A1 (en) 2020-07-16
EP3908311A1 (en) 2021-11-17
WO2020144614A1 (en) 2020-07-16
CL2021001835A1 (es) 2022-01-21
US20240139265A1 (en) 2024-05-02
US20200222478A1 (en) 2020-07-16
MA54693A (fr) 2021-11-17
CO2021010006A2 (es) 2021-08-30
MX2021008392A (es) 2021-10-26
KR20210113655A (ko) 2021-09-16
CR20210370A (es) 2021-09-09
TW202043256A (zh) 2020-12-01
UY38542A (es) 2020-07-31
CA3126462A1 (en) 2020-07-16
AU2020207641A1 (en) 2021-07-22
JP2022516770A (ja) 2022-03-02
PE20211660A1 (es) 2021-08-26
SG11202107274VA (en) 2021-07-29
BR112021013507A2 (pt) 2021-11-16

Similar Documents

Publication Publication Date Title
CR20210370A (es) Neoantígenos prostáticos y sus usos
ZA201904623B (en) Modulating expression of polypeptides via new gene switch expression systems
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
PH12018501628A1 (en) Optimized factor viii genes
MX2019003445A (es) Proteinas de fusion inmunomoduladoras.
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
MX2019002903A (es) Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos.
AU2018273963A1 (en) Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
PH12020551134A1 (en) Fc variants with enhanced binding to fcrn and prolonged half-life
MX2016002208A (es) Polipeptidos de union a c5.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
EA201792274A1 (ru) Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения
MX2015012281A (es) Proteinas de union a tnf mejoradas.
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
AU2018276376A1 (en) Cell culture methods
MX2022009988A (es) Neoantigenos expresados en mieloma multiple y sus usos.
PH12020500087A1 (en) Immunogenic compositions comprising cea muc1 and tert
WO2013138259A3 (en) Polypeptides for treating and/or limiting influenza infection
JOP20220185A1 (ar) المستضدات المستحدثة المعبر عنها في سرطان المبيض واستخداماتها
MX2021005308A (es) Receptores de celulas t especificos para mesotelina y su uso en inmunoterapia.
EA202191919A1 (ru) Неоантигены предстательной железы и их применение